跳至主要内容
临床试验/NCT03909581
NCT03909581Unknown不适用

Randomized Study Of Endoscopic Coronary Arterial Bypass Versus Percutaneous Coronary Intervention for Left Anterior Descending Artery Revascularization

National Research Center of Surgery, Russia2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2018年2月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
2
主要终点
MACCE

研究概览

简要总结

The purpose of this study is to determine which treatment option is better for patients who have isolated coronary artery disease (blockages of one vessel supplying blood to the heart muscle). The treatment options compared in this study are:

  1. Endoscopic coronary arterial bypass
  2. Percutaneous Coronary Intervention. This study is aimed to determine the best treatment for patients with coronary artery disease.

详细描述

Coronary artery disease (CAD), also known as coronary heart disease (CHD) involves the progressive narrowing of the arteries that nourish the heart muscle. CAD is the main cause of death in Russia.

Patients with LAD disease have worse coronary flow outcomes Currently established types of myocardial revascularization are coronary artery bypass grafting (CABG) and percutaneous coronary interventions (PCI). High effectiveness of CABG was proved by multiple studies. PCI is a first line therapy in the treatment of one vessel disease due to the less invasive approach and current technological possibilities of this revascularization method.

However, the established gold standard of multivessel coronary blockage treatment is CABG. It was reflected in the latest ESC/EACTS Guidelines on Myocardial Revascularization, due to the better early and late outcomes associated with the graft specifics.

On the other hand, standard CABD operation has a high injury and morbidity rate, which were factors for development of less invasive techniques of CABG.

According to the latest ESC/EACTS guidelines there are no advantages between PCI and CABG in the LAD disease treatment, both methods are Class I; level of evidence A.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The presence of isolated lesions of LAD are available for revascularization PCI and EndoCAB
  • Suitable candidate for both PCI and EndoCAB as determined by clinical assessment and angiogram review by an interventional cardiologist and a cardiac surgeon at the enrolling clinical site
  • Age ≥ 18 years

排除标准

  • Previous cardiac surgery of any kind, including CABG
  • Previous thoracic surgery involving the left pleural space
  • Need for concomitant vascular or other cardiac surgery during the index hospitalization (including, but not limited to, valve surgery, aortic resection, left ventricular aneurysmectomy, and carotid endarterectomy or stenting)
  • Indication for chronic oral anticoagulation therapy at the time of randomization
  • Extra-cardiac illness that is expected to limit survival to less than 5 years
  • Allergy or hypersensitivity to any of the study drugs or devices used in the trial
  • Therapy with an investigational drug, device or biologic within 1 year prior to randomization, or plan to enroll patient in additional investigational study during participation in this trial
  • Unable to give informed consent or potential for noncompliance with the study protocol in the judgment of the investigator
  • Ejection fraction of 40% or less Left ventricular dysfunction

研究组 & 干预措施

Endoscopic coronary arterial bypass

Active Comparator

is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization

干预措施: Endoscopic coronary arterial bypass (Procedure)

Percutaneous Coronary Intervention

Active Comparator

will be performed using standard techniques at the discretion of the operator

干预措施: Percutaneous Coronary Intervention (Procedure)

结局指标

主要结局

MACCE

时间窗: 1 year

Major adverse cardiac and cerebral events (MACCE), including death,a composite of major cardiac and cerebrovascular events, i.e. the first occurrence of any of the following events: Death from any cause From cardiovascular causes From noncardiovascular causes Stroke or transitory ischemic attack (TIA) MI Hospitalization for repeat revascularization procedure, target (vessel) revascularization by means of PCI or CABG.

次要结局

  • Pain assessment(1 year)
  • Procedural success(1 year)

研究者

发起方
National Research Center of Surgery, Russia
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Vadim Popov

M.D., Ph.D, Prof. Head of cardiovascular Department

National Research Center of Surgery, Russia

研究点 (2)

Loading locations...

相似试验